FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% of patients Confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate th ...

Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing. In many instances, however, early signs of trouble creep in. Sensible investors can identify potential issues from declining financial reports, brewing service problems, poorly managed spending, or questionable business decisions. Unfortunately, these three companies all show these signs, which may mean things ar ...

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be ke ...

| --- | --- | |-------------------------------------------------------------------------|---------------------------------------| | | | | Pancreatic tumor preclinical models demonstrate that CTGF: | Pamrevlumab has multiple effects in | | • Promotes proliferation | pancreatic cancer preclinical models: | | • Decreases apoptosis and promotes survival | • Increased survival | | • Supports invasion | • Promoted tumor cell apoptosis | | • Stimulates fibroblast activation, proliferation, and ECM deposition | • R ...

FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Conference Call February 26, 2024 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Thane Wettig - Chief Executive Officer John Hunter - Chief Scientific Officer Juan Graham - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Paul Choi - Goldman Sachs Operator Thank you for standing by and welcome to FibroGen's Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instruction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 409 Illinois Street (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results SAN FRANCISCO, February 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company's recent developments. "We are extremely excited about the company's prospects in 2024," said Thane Wettig, Chief Executive Officer, FibroGen. "In this year alone, we will obtain data read-outs from our two late-stage pancreatic cance ...

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. To register, click here. The event will feature Andrew Ko, MD (University of California San Francisco (UCSF), UCSF's Helen Diller Family Comprehensive Cancer Center) and Vincent Picozzi, MD, MMM (Virginia Mason Digestive Disease and Cancer Institutes, Virginia Mason Medical Center), who will discuss the unmet me ...

FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Thane Wettig - Chief Executive Officer Juan Graham - Chief Financial Officer John Hunter - Chief Scientific Officer Mark Eisner - Chief Medical Officer Chris Chung - Senior Vice President of China Operations Conference Call Participants Operator Hello and welcome to the FibroGen's Third Quarter 2023 Earnings Call. At this time, all partici ...

Significant commercial potential • PDAC: Safe and well tolerated with dose and exposure-related response, trend for improved resection rate, and increased completion of chemotherapy cycles • Phase 3 programs in areas of high unmet medical need with limited late-stage competitive intensity • PDAC: Multi-billion-dollar revenue opportunity, if successful 5 Recently Announced and Upcoming Pamrevlumab Milestones 3Q 2023 1H 2024 • Announced negative topline results from phase 3 LELANTOS-2 trial in ambulatory DMD ...